Suppr超能文献

降糖药物作为成人 1 型糖尿病辅助治疗的疗效和安全性比较:系统评价和网络荟萃分析。

Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.

机构信息

Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Diabetes Centre, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.

出版信息

Diabetes Obes Metab. 2021 Mar;23(3):822-831. doi: 10.1111/dom.14291. Epub 2021 Jan 6.

Abstract

AIM

To assess the efficacy and safety of glucose-lowering drugs used as an adjunct to insulin therapy in adults with type 1 diabetes.

METHODS

We searched Medline, Embase and the Cochrane Central Register of Controlled Trials up to 24 January 2020 for randomized controlled trials. Our primary outcome was change in HbA1c. We additionally assessed eight efficacy and six safety secondary endpoints. We performed random effects frequentist network meta-analysis to estimate mean differences (MDs) and odds ratios (ORs), alongside 95% confidence intervals (CIs). We assessed risk of bias and evaluated confidence in the evidence for the primary outcome.

RESULTS

We included 58 trials comprising 13 216 participants. Overall, sodium-glucose co-transporter (SGLT) inhibitors, liraglutide, glibenclamide, acarbose and metformin reduced HbA1c compared with placebo (MDs ranging from -0.46% [95% CI -0.64% to -0.29%] for empagliflozin to -0.20% [-0.35% to -0.06%] for metformin). SGLT inhibitors, exenatide daily, liraglutide and metformin reduced body weight and total daily insulin dose, while liraglutide and SGLT inhibitors reduced blood pressure. Diabetic ketoacidosis and genital infections were more frequent with SGLT inhibitors, while exenatide, liraglutide, pramlintide and metformin increased the incidence of nausea. No drug increased the incidence of severe hypoglycaemia. Confidence in evidence was mainly moderate to very low.

CONCLUSIONS

Specific drugs may improve glycaemic control and reduce body weight, blood pressure and total daily insulin dose in patients with type 1 diabetes. However, low quality of evidence and an increased risk of diabetic ketoacidosis, genital infections or gastrointestinal adverse events should be taken into consideration by healthcare providers and patients. Future long-term trials are needed to clarify their benefit-to-risk profile and elucidate their role in clinical practice.

摘要

目的

评估在 1 型糖尿病成人患者中,作为胰岛素治疗辅助手段的降糖药物的疗效和安全性。

方法

我们检索了 Medline、Embase 和 Cochrane 对照试验中心注册库,检索时间截至 2020 年 1 月 24 日,以获取随机对照试验。我们的主要结局是糖化血红蛋白(HbA1c)的变化。我们还评估了 8 项疗效和 6 项安全性次要结局。我们采用随机效应频率网络荟萃分析来估计平均差异(MDs)和比值比(ORs),以及 95%置信区间(CIs)。我们评估了偏倚风险,并对主要结局的证据可信度进行了评估。

结果

我们纳入了 58 项试验,共计 13216 名参与者。总体而言,钠-葡萄糖共转运蛋白(SGLT)抑制剂、利拉鲁肽、格列本脲、阿卡波糖和二甲双胍与安慰剂相比降低了 HbA1c(范围从恩格列净的 -0.46%[95%CI -0.64%至-0.29%]至二甲双胍的 -0.20%[-0.35%至-0.06%])。SGLT 抑制剂、每日艾塞那肽、利拉鲁肽和二甲双胍降低了体重和每日总胰岛素剂量,而利拉鲁肽和 SGLT 抑制剂降低了血压。SGLT 抑制剂、生殖器感染更为常见,而艾塞那肽、利拉鲁肽、普兰林肽和二甲双胍增加了恶心的发生率。没有药物增加严重低血糖的发生率。证据的可信度主要为中等到极低。

结论

特定药物可能改善 1 型糖尿病患者的血糖控制,并降低体重、血压和每日总胰岛素剂量。然而,医护人员和患者应考虑到低质量证据和增加糖尿病酮症酸中毒、生殖器感染或胃肠道不良事件的风险。需要进行未来的长期试验来阐明其获益-风险特征,并阐明其在临床实践中的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验